Amgen builds structural damage claims
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amgen/Wyeth's Enbrel (etanercept) sBLA for "inhibiting the progression of structural damage of active arthritis in patients with psoriatic arthritis" clears FDA Aug. 21. Amgen's interleukin-1 receptor antagonist Kineret (anakinra) also clears FDA Aug. 22 with a supplemental indication for slowing progression of structural damage in moderately to severely active rheumatoid arthritis (1Pharmaceutical Approvals Monthly Nov. 1, 2002, p. 9)...
You may also be interested in...
Amgen Submits Kineret, Enbrel sBLAs; Triangle Files Coviracil NRTI
Amgen’s Kineret Oct. 21 sBLA for a claim to inhibit progression of structural damage in adults with moderately to severely active rheumatoid arthritis is based on a single 12-month, double-blind, placebo-controlled trial.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.